Skip to content
Generic

Schizophrenia and increased risks of cardiovascular disease

Hennekens C, Hennekens A, Hollar D, Casey D ...see all

American Heart Journal, vol. 150, issue 6 (2005) pp. 1115-1121

  • 205

    Readers

    Mendeley users who have this article in their library.
  • 576

    Citations

    Citations of this article.
  • 9.4k

    Views

    ScienceDirect users who have downloaded this article.
Sign in to save reference

Abstract

Objective: The aim of the study is to review the absolute and relative impacts of the major causes for premature mortality among patients with schizophrenia. Data sources: We reviewed published articles on causes of mortality in the general population as well as among patients with schizophrenia. Study selection: We selected articles which published total and cause-specific mortality rates. Data extraction: We reviewed the causes of mortality and their risk factors. Data synthesis: The average life expectancy of the general population is 76 years (72 years in men, 80 years in women), whereas the corresponding figure is 61 years (57 years in men, 65 years in women) among patients with schizophrenia. Thus, patients with schizophrenia have approximately a 20% reduced life expectancy compared with the general population. Although patients with schizophrenia are 10 to 20 times more likely than the general population to commit suicide, more than two thirds of patients with schizophrenia, compared with approximately one-half in the general population, die of coronary heart disease (CHD). The chief risk factors for this excess risk of death are cigarette smoking, obesity leading to dyslipidemia, insulin resistance and diabetes, and hypertension. Conclusions: The chief cause of excess premature mortality among patients with schizophrenia is CHD, caused mainly by their adverse risk factor profile. Because patients with schizophrenia have less access to medical care, consume less medical care, and are less compliant with their regimens, the choice of antipsychotic drug regimens that do not further adversely affect their risk factor for CHD is a major clinical and public health challenge among patients with schizophrenia. ?? 2005, Mosby, Inc. All rights reserved.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Charles H. Hennekens

  • Alissa R. Hennekens

  • Danielle Hollar

  • Daniel E. Casey

Cite this document

Choose a citation style from the tabs below